Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Management attributes the successful transition to Phase II/III clinical stages to the unique 'immune rebalancing' mechanism of soquelitinib, which resets rather than just suppresses the immune system. The 2025 performance was driven by Phase I atopic dermatitis (AD) data showing a 72% mean EASI reduction, which management claims positions the drug among the most active oral or injectable agents. Strategic positioning is focused on 'unfavorable' patient populations, specifically those refractory to prior systemic therapies like Dupixent and JAK inhibitors, where soquelitinib maintained efficacy while placebo cohorts failed. Operational execution is highlighted by the induction of T regulatory cells (Tregs), a novel biomarker discovery that management believes explains the observed lack of disease rebound after stopping therapy. The company successfully leveraged
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.MarketBeat
- Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
CRVS
Earnings
- 3/12/26 - Miss
CRVS
Sec Filings
- 3/13/26 - Form 8-K
- 3/13/26 - Form 424B5
- 3/13/26 - Form S-3ASR
- CRVS's page on the SEC website